Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ProQR Therapeutics N.V. (PRQR : NSDQ)

• Company Description    ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. Number of Employees: 150

• Price / Volume Information    Yesterday's Closing Price: $0.67 Daily Weekly Monthly 20 Day Moving Average: 1,193,901 shares Shares Outstanding: 71.29 (millions) Market Capitalization: $48.06 (millions) Beta: 0.97 52 Week High: $9.09 52 Week Low: $0.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.87% 0.38% 12 Week -34.55% -28.06% Year To Date -91.58% -90.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ZERNIKEDREEF 9 - LEIDEN,P7 2333 CK NLD ph: 31-88-166-7000 fax: - ir@proqr.com http://www.proqr.com

• General Corporate Information    Officers Daniel de Boer - Chief Executive Officer Theresa Heggie - Chief Operating Officer Smital Shah - Chief Business and Financial Officer Aniz Girach - Chief Medical Officer Naveed Shams - Chief Scientific Officer Peer Information ProQR Therapeutics N.V. (CORR.) ProQR Therapeutics N.V. (RSPI) ProQR Therapeutics N.V. (CGXP) ProQR Therapeutics N.V. (BGEN) ProQR Therapeutics N.V. (GTBP) ProQR Therapeutics N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N71542109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 71.29 Most Recent Split Date: (:1) Beta: 0.97 Market Capitalization: $48.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.43 Price/Cash Flow: - Price / Sales: 16.13 EPS Growth vs. Year Ago Period: 26.67% vs. Previous Quarter: 26.67% Sales Growth vs. Year Ago Period: 714.71% vs. Previous Quarter: 407.33% ROE 03/31/22 - -54.60 12/31/21 - -59.74 09/30/21 - -65.00 ROA 03/31/22 - -33.17 12/31/21 - -37.01 09/30/21 - -41.70 Current Ratio 03/31/22 - 7.27 12/31/21 - 6.94 09/30/21 - 5.10 Quick Ratio 03/31/22 - - 12/31/21 - 6.94 09/30/21 - 5.10 Operating Margin 03/31/22 - -2,469.79 12/31/21 - -4,113.78 09/30/21 - -3,747.12 Net Margin 03/31/22 - -2,469.79 12/31/21 - -4,113.78 09/30/21 - -3,747.12 Pre-Tax Margin 03/31/22 - -2,478.65 12/31/21 - -4,546.50 09/30/21 - -3,730.07 Book Value 03/31/22 - 1.58 12/31/21 - 1.88 09/30/21 - 3.01 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.38 12/31/21 - 0.35 09/30/21 - 0.14 Debt-to-Capital 03/31/22 - 27.69 12/31/21 - 25.77 09/30/21 - 12.03

Powered by Zacks Investment Research ©